重塑免疫抑制肿瘤微环境增强免疫治疗的研究进展  

Research progress in remodeling immunosuppressive tumor microenvironment to enhance immunotherapy

作　　者：王涵泳 张琳华[1] 朱敦皖[1] Wang Hanyong;Zhang Linhua;Zhu Dunwan(Institute of Biomedical Engineering,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300192,China)

机构地区：[1]中国医学科学院北京协和医学院生物医学工程研究所,天津300192

出　　处：《国际生物医学工程杂志》2024年第4期388-394,共7页International Journal of Biomedical Engineering

基　　金：国家自然科学基金(82172090, 82302390, 82072059)。

摘　　要：利用人体自身免疫系统对抗癌症的免疫疗法已经成为癌症治疗的主流临床策略之一, 被批准应用于临床治疗的免疫治疗药物逐年增加。然而, 具有免疫抑制能力的肿瘤微环境明显降低了免疫治疗的效果, 使免疫治疗存在应答率低、渗透性差等问题, 临床疗效并不理想。主要综述了通过减少免疫抑制细胞和可溶性分子重塑免疫抑制肿瘤微环境(ITME)的方法和作用机制, 探讨联合化疗、放疗等其他治疗方式对重塑ITME的关键作用, 以增强免疫治疗效果。Immunotherapy,which utilizes the body’s own immune system to fight cancer,has become one of the mainstream clinical strategies for cancer treatment,and the number of immunotherapeutic drugs approved for clinical treatment has increased year by year.However,the tumor microenvironment with immunosuppressive ability significantly reduces the effect of immunotherapy,making immunotherapy suffer from low response rate,poor penetration,and other problems,and the clinical efficacy is not ideal.In this review paper,the methods and mechanisms of action of remodeling the immunosuppressive tumor microenvironment(ITME)by reducing immunosuppressive cells and soluble molecules were summarized,and the important role of combined chemotherapy,radiotherapy,and other therapeutic modalities was explored in remodeling the ITME and enhancing the efficacy of immunotherapy.

关 键 词：免疫抑制 肿瘤微环境 免疫治疗 联合治疗 

分 类 号：R730.51[医药卫生—肿瘤]